AstraZeneca (AZ) is to assist Biovator in the development of its
in vitro test for identifying potential allergens that
could replace many experiments on animals.
As pharma firms disclose their financial results for the second
quarter of the year, AstraZeneca (AZ) and Bristol-Myers Squibb
(BMS) have announced more job cuts.
In a deal worth up to $1.35bn (€1bn) AstraZeneca (AZ) have agreed
to co-develop and commercialise two of Bristol-Myers Squibb's (BMS)
late stage diabetes compounds.